PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells

Twelve-week treatment with rosiglitazone improved EPC number and migratory activity of type 2 diabetic patients. The latter mechanism may contribute to the recently observed improvement of endothelial function by rosiglitazone in type 2 diabetes.